Veracyte Inc (VCYT) 銘柄情報

VCYT! 10Q due MONDAY 2/24

VCYT under $20 a buy

Anyone got any idea what's going on with this in the last two days?? Only good news and it's down HUGELY??

VCYT buy 23.8101



normal chart







log chart

Yep....

* * $VCYT Video Chart 10-31-18 * *

Link to Video - click here to watch the technical chart video

$VCYT recent news/filings

bearish 4.76

## source: finance.yahoo.com

$VCYT charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$VCYT company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/VCYT/company-info
Ticker: $VCYT
OTC Market Place: Not Available
CIK code: not found
Company name: Veracyte Inc.
Incorporated In:
$VCYT share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$VCYT extra dd links

Company name: Veracyte Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/VCYT/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/VCYT/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=VCYT+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=VCYT+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=VCYT+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/VCYT/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/VCYT/news - http://finance.yahoo.com/q/h?s=VCYT+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/VCYT/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/VCYT/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/VCYT/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/VCYT/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/VCYT/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/VCYT/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/VCYT/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/VCYT/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=VCYT+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/VCYT
DTCC (dtcc.com): http://search2.dtcc.com/?q=Veracyte+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Veracyte+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Veracyte+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/VCYT/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/VCYT
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/VCYT/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/VCYT/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/VCYT/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/VCYT/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/VCYT/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/VCYT/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/VCYT/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=VCYT&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=VCYT
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/VCYT/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=VCYT+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=VCYT+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=VCYT
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=VCYT
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=VCYT+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/VCYT/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=VCYT+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/VCYT.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=VCYT
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/VCYT/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/VCYT/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/VCYT/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/VCYT/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/VCYT
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/VCYT
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/VCYT:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=VCYT
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=VCYT



$VCYT DD Notes ~ http://www.ddnotesmaker.com/VCYT

Hey. Anyone following this stock? I've been averaging down from 14s to 7s and wondering when it will show some reversal.

starbuxsux, thanks for sharing.

Veracyte, Inc. Announces Closing of Initial Public Offering

4:26 PM ET 11/4/13 | PR Newswire

Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its initial public offering of 5,000,000 shares of its common stock resulting in net proceeds of approximately $58.0 million after deducting underwriting discounts and commissions and estimated expenses. All of the shares of common stock were offered by Veracyte at a price to the public of $13.00 per share.

Morgan Stanley and Leerink Swann acted as joint book-running managers for the offering. William Blair and Cowen and Company acted as co-managers.

A copy of the final prospectus relating to the offering may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, New York, NY 10014, telephone: 1-866-718-1649, or email: prospectus@morganstanley.com; or Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, telephone: 1-800-808-7525 or email: Syndicate@Leerink.com.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 29, 2013. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such state or jurisdiction.

About Veracyte, Inc.

Veracyte is focused on discovering, developing and commercializing molecular cytology solutions that enable physicians to make more informed treatment decisions at an early stage in patient care, thus helping patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte's first commercial solution, the Afirma® Thyroid FNA Analysis, includes the Gene Expression Classifier (GEC). The GEC helps physicians reduce the number of unnecessary surgeries by employing a proprietary 142-gene signature to preoperatively determine whether thyroid nodules previously classified by cytopathology as indeterminate can be reclassified as benign. The clinical utility and cost effectiveness of the GEC have been demonstrated in studies published in peer-reviewed journals and the clinical validity of the GEC has been demonstrated in a study published in The New England Journal of Medicine in 2012. Since the commercial launch of Afirma in January 2011, Veracyte has processed over 50,000 fine needle aspiration (FNA) samples for evaluation using Afirma and has performed more than 10,000 GECs to resolve indeterminate cytopathology results. Veracyte has obtained positive coverage decisions for Afirma from Aetna, Humana, Medicare and UnitedHealthcare. Collectively, these payers represent more than 100 million covered lives. Afirma is marketed and sold in the United States through a global co-promotion agreement with Genzyme Corporation, a subsidiary of Sanofi.

Veracyte and Afirma are trademarks of Veracyte, Inc. This press release also contains trademarks and trade names that are the property of their respective owners.

Source: Veracyte

Media:Tracy Morris650-380-4413 Tracy.Morris@Veracyte.com

Investors:Angeli KolhatkarBurns McClellan, Inc.212-213-0006akolhatkar@burnsmc.com

SOURCE Veracyte

http://rt.prnewswire.com/rt.gif?NewsItemId=SF09897&Transmission_Id=201311041626PR_NEWS_USPR_____

New board.